For cancer cells, which prefer glycolysis (Warburg effect) over oxidative phosphorylation to produce intermediate metabolites and energy, enabling resistance to cuproptosis [82], p53 inhibits glycolysis and drives the metabolic switch to oxidative phosphorylation in cancer cells. This evidence concerns the gene TP53 and cancer.